Sepiapterin Methods for BH4 Disorders
Summary
USPTO published patent application US20260091037A1 for sepiapterin compositions and methods treating BH4-related disorders. Inventors Neil Smith and Jonathan Reis filed the application on May 13, 2025. The application covers methods for increasing sepiapterin plasma, CSF, and brain exposure for therapeutic use.
What changed
USPTO published patent application US20260091037A1 for sepiapterin compositions and methods of treating BH4-related disorders. The application (No. 19206193) claims compositions including sepiapterin or pharmaceutically acceptable salts thereof, and methods resulting in increased plasma, CSF, and/or brain exposure of sepiapterin. Inventors are Neil Smith and Jonathan Reis.
This is a routine patent application publication with no immediate compliance obligations. Pharmaceutical companies and researchers developing BH4-related disorder treatments may wish to review the claims for potential freedom-to-operate concerns. Patent applications are informational publications only; they do not grant enforceable rights until issued as patents following examination.
Archived snapshot
Apr 3, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS FOR INCREASING SEPIAPTERIN PLASMA EXPOSURE
Application US20260091037A1 Kind: A1 Apr 02, 2026
Inventors
Neil SMITH, Jonathan REIS
Abstract
The present invention features compositions including sepiapterin, or a pharmaceutically acceptable salt thereof, and methods for the treatment of BH4-related disorders. In some embodiments, these compositions and methods result in an increase in plasma. CSF, and/or brain exposure of sepiapterin.
CPC Classifications
A61K 31/519 A61K 9/0053
Filing Date
2025-05-13
Application No.
19206193
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.